Ana Alfonso Piérola

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

David P. Steensma, Martin Wermke, Virginia M. Klimek et al. · Leukemia · 2021 · 169 citations · Full text

Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism

Ana Alfonso Piérola, David Jiménez, Carmen Fernández Capitán et al. · Thrombosis and Haemostasis · 2013 · 122 citations

Recurrent Vte, Pharmacotherapy, Logistic Analysis +23

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

Paula Rodríguez-Márquez, María Eréndira Calleja-Cervantes, Guillermo Serrano et al. · Science Advances · 2022 · 107 citations · Full text

T-regulatory Cell, Immunology, Antitumoral Efficacy +16

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier et al. · Blood · 2022 · 86 citations